Drug Profile
Emraclidine - Cerevel Therapeutics
Alternative Names: CVL-231; PF-06852231Latest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Cerevel Therapeutics; Pfizer
- Class Antidementias; Antipsychotics; Azetidines; Fluorobenzenes; Ketones; Pyridines; Pyrroles; Small molecules
- Mechanism of Action Muscarinic M4 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Schizophrenia
- Phase I Alzheimer's disease
Most Recent Events
- 15 Apr 2024 Cerevel Therapeutics plans to initiate a phase I pharmacokinetic trial (In volunteers) in May 2024 (NCT06366243)
- 08 Mar 2024 Cerevel Therapeutics initiates enrolment in a phase I pharmacokinetics trial (In volunteers, In adults) in the US (PO) (NCT06301971)
- 10 Nov 2023 Cerevel Therapeutics completes a phase I trial for Healthy volunteers in USA (PO) (NCT05965219)